See why the voice of the patient, technology integration, optimal delivery strategy and data are key in the adoption of decentralized trials.

Most pharmaceutical companies work with an average of seven bioanalytical labs in a given year, taking time and scientists away from important researc

Three biosimilars for rheumatoid arthritis (RA) were approved by the FDA last year, but the regulatory pathway in the US is still considered a new fro

Today, RA studies are taking longer and require more sites to complete. With so few patients actually participating in clinical trials, what does the

The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indic

Over the last 10 years, clinical trials have changed substantially in response to increasing globalization and study complexity, along with new techno

Clinical forecasting is now leveraging innovative informatics capabilities for more precise recruitment and endpoint projections during a study’s cruc

The clinical trial landscape is witnessing an increase in Phase III trials that average more than 3,500 patients.

Learn how integrated informatics are playing a larger role in managing large datasets, mitigating clinical trial risk and proactively maintaining pati